BEAM Stock — Beam Therapeutics Inc.

Beam Therapeutics Inc. (BEAM)

Updated October 16, 2026.

BEAM is a Stock. Total return is 25.2% over the past 6.7 years, 126.1 points behind SPY at 151.3%.

Beam Therapeutics is a biotechnology company developing precision genetic medicines for serious diseases, with a pipeline focused on treatments for conditions like sickle cell disease, alpha-1 antitrypsin deficiency, phenylketonuria, and glycogen storage disease, alongside collaborative programs with partners including Pfizer and Verve Therapeutics. As a pre-commercial biotech company, it does not currently distribute to shareholders. The company appeals to investors seeking exposure to genetic medicine innovation rather than current income.

BEAM performance versus SPY

Price and return data through 2026-10-16.

Total return is 25.2% over the past 6.7 years, 126.1 points behind SPY at 151.3%. Over the past year its total return — price change plus distributions reinvested — is -9.0%. Its deepest 1-year drawdown was 39.1%.

BEAM key facts

Asset type

Stock

Asset class

Equity

Inception date

02/06/2020

Distribution frequency

None

Last close

$23.47 (as of 2026-10-16)

Market cap

$2,424,161,498

Average volume

1645136.0

Beta

2.201

Payout ratio

0.0%

EPS

$-0.68

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BEAM risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 39.1%.

Who may consider BEAM — and who may not

It is a weaker fit for investors who need monthly cash flow (BEAM does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BEAM

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions